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TDP-43 PATHOLOGY IN CHRONIC TRAUMATIC ENCEPHALOPATHY 
DOUGLAS BARNES 
ABSTRACT  
Transactive response DNA-binding protein of 43 kDa (TDP-43) is the major 
protein found within pathological inclusions in Amyotrophic Lateral Sclerosis (ALS) and 
Frontotemporal Lobar Degeneration (FTLD) (Neumann et al., 2006).  TDP-43 is a 
ubiquitously expressed protein mainly involved in RNA metabolism.  It is a member of 
the heterogeneous nuclear ribonucleoprotein (hnRNP) family and in its normal state is 
predominantly found in the nucleus.  In its pathological state TDP-43 is cleaved, 
phosphorylated, ubiquitinated, and located in cytoplasmic or nuclear inclusions.   
Along with ALS and FTLD, TDP-43 is also observed in many other 
neurodegenerative diseases.  Pathological TDP-43 inclusions have been previously 
reported in cases of Chronic Traumatic Encephalopathy (CTE) (King et al., 
2010)(McKee et al., 2010)(Saing et al., 2012)(Hazrati et al., 2013), however no previous 
study has reported on the incidence and extent of TDP-43 cellular inclusions in a large 
cohort of autopsy cases diagnosed with CTE.   
This study finds that TDP-43 inclusions are a frequent feature of CTE, as TDP-43 
inclusions are identified in 43% (20/47) of subjects in a CTE+, FTLD-, low-likelihood-
of-AD cohort.  Furthermore, this study finds that in CTE there is no consistent initial 
focus of TDP-43 pathology which spreads to neighboring regions as the disease 
progresses.  Despite the lack of a clear progression of TDP-43 pathology, a TDP Staging 
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Scheme for CTE which accurately reflects the extent and severity of TDP-43 pathology 
in not only the study cohort, but likely in all subjects without FTLD, was established.   
Four stages were identified: TDP Stage 0 showed no TDP-43 inclusions in the 
substantia nigra, dorsolateral frontal cortex, or dentate gyrus; TDP Stage 1 showed 
inclusions in either the substantia nigra or the dorsolateral frontal cortex; TDP Stage 2 
showed inclusions either in the dentate gyrus or in both the substantia nigra and the 
dorsolateral frontal cortex; and TDP Stage 3 showed inclusions in the substantia nigra, 
dorsolateral frontal cortex, and dentate gyrus. 
 Finally, a correlation was found between the presence of TDP-43 inclusions and 
the levels of activated microglia in the dorsolateral frontal cortex of CTE+ subjects.  This 
finding aligns with the theory that the pathological changes of TDP-43 found in CTE are 
driven by the pro-inflammatory cytokines released by chronically activated microglia.         
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INTRODUCTION  
In 2006, Neumann et al. described transactive response DNA-binding protein of 
43 kDa (TDP-43) as the major protein within ubiquitinated cellular inclusions found in 
both frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) 
(Neumann et al., 2006).  TDP-43 cellular inclusions have since been found in a growing 
number of neurodegenerative diseases, including FTLD with Pick Bodies (Arai et al., 
2006), Alzheimer’s Disease (Amandor-Ortiz et al., 2007), Dementia With Lewy Bodies 
(Nakashima-Yasuda et al., 2007), Argyrophilic Grain Disease (Fujishiro et al., 2008), 
Huntington Disease (Schwab et al., 2008), Progressive Supranuclear Palsy (Yokota et al., 
2010), Corticobasal Degeneration (Yokota et al., 2010), and Hippocampal Sclerosis (Pao 
et al., 2011). 
TDP-43 immunoreactivity was first reported in cases of Chronic Traumatic 
Encephalopathy (CTE) in 2010 (King et al., 2010).  Since this original report, the finding 
has been confirmed by several studies, each examining a small number of cases (McKee 
et al., 2010)(Saing et al., 2012)(Hazrati et al., 2013).  To date, no previous study has 
reported on the incidence and extent of TDP-43 cellular inclusions in a large cohort of 
autopsy cases previously diagnosed with CTE.   
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Normal TDP-43 Structure and Function 
 
Figure 1: TDP-43 Structure.  Adapted from Chang et al., 2015. 
  
 
TDP-43 is a 414 amino acid protein encoded by the TARDBP gene on chromosome 1 
which contains the following elements (Figure 1): 
- Nuclear Localization Sequence (NLS): Spans amino acids (AAs) 82-98 (Winton 
et al., 2008).  Together with the Nuclear Export Sequence allows the protein to 
shuttle between the nucleus and cytoplasm (Mackness et al., 2014). 
- RNA Recognition Motif 1 (RRM1): Spans AAs 106-196, necessary for normal 
TDP-43 function.  Recognizes RNA with a minimum of five UG repeats and 
shows increased binding affinity to longer sequences of repeats (Tollervey et al., 
2011). 
- RNA Recognition Motif 2 (RRM2): Spans AAs 191-262, Binds shorter UG 
repeats with a higher affinity than RRM1 (Lukavsky et al., 2013). 
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- Nuclear Export Signal (NES): Putative NES is within RRM2 and spans AAs 236-
247.  Together with NLS allows the protein to shuttle between the nucleus and 
cytoplasm (Mackness et al., 2014). 
- Glycine Rich Domain: Spans AAs 274-314 according to some (Ou et al., 1995), 
according to others spans almost the entire C-terminal after RRM2, AAs 274-414 
(Pesiridis et al., 2009).    
- Prion-like Glutamine/Asparagine Rich (Q/N Rich) Domain: Spans AAs 320-367 
(Fuenteabla et al., 2010).  This domain is necessary for TDP-43 autoregulation 
(Y. M. Ayala et al., 2011).    
 
Primarily a nuclear protein, TDP-43 is also found in low levels in the cytoplasm 
(Lee et al., 2011).  TDP-43 expression is not unique to the brain, as TDP-43 has been 
found in a variety of tissues. A 2001 study found TDP-43 to be expressed in all sixteen 
human tissues tested, with the highest levels found in the pancreas, placenta, spleen, 
ovaries, and testis (Buratti et al., 2001). 
 TDP-43 was originally discovered by Ou et al. in 1995 as a protein that binds 
TAR DNA motifs of the human immunodeficiency virus type 1 (HIV-1) (Ou et al., 
1995).  Further research identified it as a member of the heterogeneous nuclear 
ribonucleoprotein (hnRNP) family, a group of proteins mainly involved in RNA 
metabolism (Buratti et al., 2010).  TDP-43 has numerous functions within the cell, 
including regulation of pre-mRNA splicing (Buratti et al., 2001), miRNA processing 
(Buratti et al., 2010)(Kawahara et al., 2012), mRNA stability (Volkening et al., 
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2009)(Fiesel et al., 2010), mRNA transport and local translation (Wang et al., 2008), and 
autoregulation (Y. M. Ayala et al., 2011). 
 
Pathological TDP-43 
The pathological form of TDP-43 is ubiquitinated, phosphorylated, cleaved, and 
located in intracellular cytoplasmic inclusions (Neumann et al., 2006).  When TDP-43 
was originally identified as the major disease protein in FTLD-U and ALS by Neumann 
and colleagues in 2006 it was hoped that TDP-43 inclusions were a specific marker for 
those two diseases.  A study published later that year began to cast doubt on this thinking, 
however, by reporting the finding of Pick bodies, normally characterized by the presence 
of pathological tau protein inclusions, with TDP-43 inclusions (Arai et al., 2006).  Soon 
after, the findings of that study were confirmed (Freeman et al., 2008), and TDP-43 
inclusions were found in many other diseases.  Notably, TDP-43 inclusions are not 
limited to the cells of the central nervous system, as they have also been found in muscle 
cells of patients suffering from several types of myopathies with rimmed vacuoles 
(Kusters et al., 2008).   
 
Loss or Gain of Function? 
Three possible hypotheses have been offered up to explain how TDP-43 may 
cause cellular toxicity: a loss of function hypothesis, a gain of function hypothesis, and a 
dominant-negative hypothesis (Yang et al., 2010)(Lee et al., 2011)(Li et al., 
2013)(Vanden Broeck et al., 2014).  Under the loss of function hypothesis, when TDP-43 
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is cleared from the nucleus and localized into cytoplasmic inclusions the cell loses vital 
TDP-43 function and degenerates.  Under the gain of function hypothesis, soluble and/or 
aggregated TDP-43 accumulates in the cytoplasm and gains novel toxic properties.  
Under the dominant-negative mechanism, TDP-43 fragments interfere with the protein’s 
normal function and the cell loses vital TDP-43 function.  It should be noted that these 
processes are not mutually exclusive and a combination of two or all three may be at 
work (Vanden Broeck et al., 2014). 
 
TDP-43 Modifications Associated with Neurodegeneration 
 TDP-43 within cellular inclusions may be cleaved, phosphorylated, and 
ubiquitinated (Neumann et al., 2006).  At this time, however, the significance of these 
changes has not been established.     
 
Figure 2: Normal vs. Pathological State of TDP-43 
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Cleavage 
 TDP-43 inclusions in patients suffering from ALS and FTLD-TDP contain both 
full length TDP-43 (FL-TDP-43) and TDP-43 C-terminal fragments of 25 kDa (CTF-
25)(Neumann et al., 2006)(Igaz et al., 2008), but minimal or no N-terminal fragments 
(Kwong et al., 2014).  Additionally, C-terminal fragments of 35 kDa (CTF-35) may also 
be found within inclusions in these patients (Zhang et al., 2007), but their presence is 
variable (Lee et al., 2011).   
These CTFs are generated by the cleavage of TDP-43 by several different 
enzymes.  The majority of studies have focused on caspase-3, which is a key executioner 
of apoptosis (Li et al., 2015) but is also involved in many cellular processes which do not 
lead to apoptosis (Shalini et al., 2014).  Recent studies have provided evidence that 
calpain, which is activated by intracellular calcium ions, cleaves cytoplasmic TDP-43 in 
vivo, as well (Yamashita et al., 2012)(Yang et al., 2014).  Asparaginyl endopeptidase, the 
only known mammalian enzyme capable of cleaving C-terminal to asparagine residues, 
has also been shown to cleave TDP-43 in vivo (Herskowitz et al., 2012).  Notably, low 
levels of soluble, non-aggregated CTF-25 and CTF-35 are found in cells under control 
conditions (Dormann et al., 2009)(Nishimoto et al., 2010), and these fragments may be 
degraded by the proteasome (Bose et al., 2011)(I.-F. Wang et al., 2012)(Caccamo et al., 
2015). 
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Phosphorylation 
TDP-43 phosphorylation is used as a marker for pathological inclusion formation 
because phosphorylation and aggregation are highly correlated (Lee et al., 2011).  FL-
TDP-43 and CTFs may be phosphorylated by multiple kinases (Iguchi et al., 
2012)(Liachko et al., 2014) at Ser379, Ser403, Ser404, Ser409, and Ser410 (Hasegawa et 
al., 2008).  Experimental evidence strongly suggests that phosphorylation occurs in the 
cytoplasm after the conversion from detergent soluble to insoluble species (Nishimoto et 
al., 2010)(Dormann et al., 2009)(Budini et al., 2012).  Although it has been shown that 
the phosphorylation of TDP-43 is neither necessary nor sufficient for inclusion formation 
(Dormann et al., 2009)(Zhang et al., 2009), its effects on the formation of TDP-43 
oligomers and microaggregates are still unclear.   
It has been reported in cell culture studies that phosphorylation of the 220-414 
CTF increases aggregation and confers resistance to degradation (Zhang et al., 2010), and 
thus favors inclusion formation.  Conversely, it has also been reported that 
phosphorylation decreases aggregation propensity (Brady et al., 2011)(Li et al., 2011), 
and so the phosphorylation of aggregates may actually be a protective mechanism meant 
to inhibit further aggregation (Li et al., 2011).    
Additionally, it is unknown whether the phosphorylation of TDP-43 influences 
the protein’s function or toxicity.  Experiments in C. elegans have shown that 
phosphorylation is required for TDP-43 neurotoxicity (Liachko et al., 2010)(Choksi et al., 
2014).  However, this effect on toxicity may be unique to the phosphorylation of human 
TDP-43 in C. elegans, as it has been shown in many other models that the 
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phosphorylation of TDP-43 or CTFs doesn’t affect toxicity (Zhang et al., 2009).  Taken 
altogether, the evidence suggests that the earlier hypothesis of phosphorylation as a 
marker of insolubility but not a driver of aggregation or cell death (Dormann et al., 2009) 
is correct.    
 
Ubiquitination        
FL-TDP-43 and CTFs within cellular inclusions may be ubiquitinated (Neumann 
et al., 2006), but the specific TDP-43 residues that are tagged have not yet been described 
and no functional consequences of ubiquitination have been identified.  Cytoplasmic 
TDP-43 has been shown to be ubiquitinated by the ubiquitin-conjugating enzyme 
UBE2E3 and deubiquitinated by ubiquitin isopeptidase Y (UBPY) (Hans et al., 2014), 
and aggregates may be tagged with K48- and K63-linked ubiquitin, ubiquilin-1 and -2, 
and p62 (Scotter et al., 2014).  Studies focusing on the ubiquitination of TDP-43 all 
seemingly agree that, like phosphorylation, it is a late event that occurs in the cytoplasm 
and likely does not drive inclusion formation (Igaz et al., 2009)(Li et al., 2011)(Budini et 
al., 2012)(Farrawell et al., 2015).          
 
Nuclear Clearance 
Cells with TDP-43 cytoplasmic inclusions exhibit clearance of nuclear TDP-43 
(Neumann et al., 2006).  The consensus among researchers is that nuclear clearance 
occurs because cytoplasmic TDP-43 inclusions have the ability to bind and sequester free 
TDP-43 floating in the cytoplasm (Winton et al., 2008)(Yang et al., 2010)(Che et al., 
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2011)(Budini et al., 2012)(Zhang et al., 2013)(Budini et al., 2015).  Although 
predominantly found in the nucleus, TDP-43 moves rapidly and continuously between 
the nucleus and the cytoplasm (Ayala et al., 2008).  The hypothesis is that because TDP-
43 is highly prone to aggregation, over time more and more free TDP-43 binds to the 
inclusion as TDP-43 is naturally shuttling between the nucleus and the cytoplasm until no 
nuclear TDP-43 is left. 
 
METHODS 
Subjects 
Forty seven subjects from the Boston University Chronic Traumatic 
Encephalopathy Center were utilized for this study.  All subjects were former athletes, 
veterans, or civilians with a history of repetitive mild traumatic brain injury and were 
previously diagnosed with CTE.  In order to select the subjects to be included in this 
study, first all subjects at the BU CTE Center diagnosed with CTE were identified.  
Second, all CTE-positive subjects examined before a certain time period where excluded 
due to a lack of sections immunostained for phosphoTDP-43.  Next, all remaining CTE-
positive subjects also diagnosed with FTLD, or with an “A” or “C” score greater than 1 
according to the criteria set forth by the National Institute on Aging – Alzheimer’s 
Association (Montine et al., 2012) were excluded from this study.  Finally, cases with 
numerous regions that were not available for examination were excluded from analysis 
but are shown in Appendix 1.             
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Immunohistochemistry 
 Human tissue was fixed in periodate-lysine-paraformaldehyde, and tissue blocks 
were paraffin-embedded and cut at 10 µm for immunohistochemistry.  Sections were 
incubated at 4 °C overnight with antibodies to phosphoTDP-43 (pS409/410 mouse 
monoclonal; Cosmo Bio Co, Tokyo, Japan; 1:2000).  Sections were counterstained with 
cresyl violet. 
  
Assessment of Neuropathological Features  
 For each subject, the following seven regions were examined by the author along 
with a neuropathologist: substantia nigra, dorsolateral frontal cortex, rolandic cortex, 
anterior temporal cortex, amygdala, entorhinal cortex, and dentate gyrus.  The severity of 
phosphoTDP-43 deposition was then graded on a 0 to 3 scale: a score of 0 indicated no 
TDP-43 inclusions on a section; a score of 1 indicated one to four TDP-43 inclusions on a 
section; a score of 2 indicated five to ten TDP-43 inclusions on a section; and a score of 3 
indicated greater than ten TDP-43 inclusions on a section.  
  
Figure 3: Regions of the brain examined.  Adapted from Micklos, 2016. 
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Statistical Analysis 
 SPSS version 23.0 (IBM Inc., Chicago, IL, USA) was utilized for statistical 
analyses.  Significance was set a priori at α = 0.05.  The Wilcoxon-Mann-Whitney U Test 
was used to compare the means between different groups (CTE Stage, Age at Death, 
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Number of Playing Years, Age at First Exposure) based on TDP-43 presence (TDP- or 
TDP+).  Logistic regression was performed to test for the effect of CTE Stage on TDP-43 
presence independent of Age at Death.  Finally, the Kruskal-Wallis H Test was used to 
compare the means between groups (Number of Effected Regions, Mean Severity of 
Affected Regions, CTE Stage) based on the TDP Staging Scheme developed in this 
study.  
 
 
 
 
 
 
 
 
RESULTS 
One hundred and thirty cases were identified as being previously diagnosed with 
CTE, and of those cases sixty one were identified as having a low likelihood of AD and 
also carrying no diagnosis of FTLD.  Of these sixty one CTE-positive cases, fourteen 
were not able to be included in this study due to incomplete information.  The 
demographic information of the final forty seven cases that were included is displayed in 
Table 1.       
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Table 1: Demographic Data 
CTE  
Stage 
Number of 
Cases 
Mean Age  
at Death 
Mean Age at  
1st Exposure 
Mean Number of 
Playing Years 
Total 47 54.2 
±18.8 
10.9 
±3.7 
16.7 
±7.2 
1 5 43.8 
±26.9 
15.3 
±2.5 
18 
±17 
2 20 48.3 
±17.7 
8.9 
±3.7 
16.1 
±6.3 
3 17 59.1 
±16.4 
11.5 
±3.3 
17.5 
±5.8 
4 
 
 
5 70.8 
±7.6 
12.5 
±0.7 
14 
±6.2 
 
Associations Between TDP-43 Inclusions, Age, and Exposure 
Subjects with TDP-43 inclusions were older at death than subjects without 
inclusions.  This does not come as a surprise, as the association between TDP-43 and age 
has been previously reported (Nakashima-Yasuda 2007)(Geser et al., 2010).  Mean CTE 
Stage, a measure of the degree and distribution of pathological tau protein inclusions, was 
also significantly higher in subjects with TDP-43 inclusions.  There was no statistically 
significant difference in the mean number of playing years, a rough estimate of the 
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number of mild traumatic brain injuries (mTBI) sustained, in subjects with CTE and 
TDP-43.  These findings are summarized in Table 2:   
 
Table 2: TDP-43 inclusions are more frequent in older subjects and in advanced CTE 
 TDP – TDP + p Value 
Number of Cases 27 20 --- 
CTE Stage 2.2 ± 0.7 2.8 ± 0.9 0.016 
Mean Age at Death 46.7 ± 16.6 64.1 ± 17.4 0.001 
Mean Age at 1st 
Exposure 
9.8 ± 3.3 12 ± 3.9 0.086 
Mean Number of 
Playing Years 
15.6 ± 9.2 17.5 ± 5 0.493 
 
Age, But Not CTE Stage, Predicts Presence of TDP-43 Inclusions 
As shown above, subjects with TDP-43 inclusions also suffered from increased 
CTE Stage (increased tau pathology).  However, as Age at Death varied significantly 
between TDP-43 groups and likely effects whether TDP-43 inclusions are present, 
logistic regression was performed to test whether CTE Stage had an effect on the 
presence of TDP-43 inclusions independent of age.  It was found that while age did have 
an effect on the presence of TDP-43 inclusions (β = 0.051, p = .019), CTE Stage did not 
have a statistically significant effect on TDP-43 inclusions after controlling for age (β = 
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0.559, p = .228).  Therefore, the presence of TDP-43 inclusions does not appear to be 
directly related to the overall severity of tau pathology within the brain. 
 
Staging TDP-43 Pathology in CTE 
TDP-43 pathology was identified in twenty out of forty seven (43%) CTE-
positive cases without FLTD and with a low likelihood of AD, as shown in Figure 4: 
 
Figure 4: TDP-43 pathology identified in nearly half of all CTE+, FTLD-, low-
likelihood-of-AD subjects 
 
 
Other studies have shown that in ALS (Brettschneider et al., 2013), AD (Josephs 
et al., 2014), and Behavioral Variant FTLD (Brettschneider et al., 2014), TDP-43 
pathology may begin in particular regions and spread, leading to the development of the 
TDP-43-based staging schemes for these diseases shown in Table 3 below: 
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Table 3: Current TDP-43-based staging schemes.  Adapted from Tan et al., 2015 
 
 
In CTE, as shown in Appendix 1 and Appendix 2, there is no consistent initial 
focus of TDP-43 pathology and no clear stereotypical pattern of progression.  Despite 
this, it is possible to accurately report the extent and severity of TDP-43 pathology in 
CTE with the staging scheme detailed in Table 4 below:    
 
Table 4: TDP-43 Staging Scheme for CTE 
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Figure 5: Regions utilized in TDP-43 Staging Scheme for CTE.  Adapted from Micklos, 
2016. 
 
 
The stages of this scheme exhibit a statistically significant difference between the 
mean number of effected regions.  This scheme also reflects disease progression as 
measured by tau pathology (CTE Stage based on tau), and so an increase in TDP-43 
Stage likely indicates a true worsening of disease.  Finally, although a statistically 
significant difference between the mean severity of TDP-43 pathology within effected 
regions was not found, this is likely due to the small number of cases in each stage and 
the limited range of the TDP severity scoring used (0=none, 1=sparse, 2=moderate, 
3=severe).  These results are summarized in Table 5 below:     
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Table 5: TDP-43 Staging Scheme accurately reports both the extent and severity of TDP-
43 pathology 
 
 
A full breakdown of how the cases in this study are staged according to this scheme is 
shown in Appendix 2.  Of note is that one case (#41) was not given a TDP Stage nor 
included in the statistical analysis shown above in Table 4 because the dentate gyrus of 
that case was not examined.  Also, one case (#4) which did exhibit TDP-43 pathology 
was given a TDP Stage of 0 according to this scheme.  Case #4, however, was the only 
case out of twenty eight Stage 0 cases which had TDP-43 inclusions, and this case 
exhibited relatively minor TDP-43 pathology.               
            
TDP-43 and Activated Microglia in the Dorsolateral Frontal Cortex 
Lastly, a statistically significant association (p<.05) was found between the 
presence of TDP-43 inclusions and levels of activated microglia in the dorsolateral 
frontal cortex of CTE cases, as soon in Figure 6 below:    
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Figure 6: TDP-43 inclusions correlate with the presence of activated microglia 
 
(Data on activated microglial cells in CTE cases kindly provided by Dr. Jonathan 
Cherry.) 
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DISCUSSION 
 
Possible to Apply This TDP Staging Scheme to All FTLD- Populations? 
 Although this TDP staging scheme was developed in a specific cohort (CTE-
positive, FTLD-negative, low-likelihood-of-AD), it may be reasonable to apply it to all 
FTLD-negative populations for two reasons: 
 
1. Studies of Control Subjects Rarely Find TDP-43 Inclusions:  
An extensive review of the literature identified six studies which reported on 
TDP-43 pathology found in cognitively normal subjects.  These six studies are detailed in 
Appendix 3.  All six studies examined the dentate gyrus and only one study identified 
TDP-43 inclusions in the dentate gyrus, and in only 12 of 323 cases.  This same study 
examined a wide variety of regions and the TDP Staging Scheme developed in this paper 
mischaracterizes TDP-43 pathology in only 7 of the 323 cases (2.2%).  Unfortunately the 
other five studies mainly focused on regions within the medial temporal lobe and so no 
definitive conclusions can be made on how often TDP-43 inclusions are found in the 
substantia nigra or the dorsolateral frontal cortex in control subjects. 
 
2. TDP-43 Inclusions Are Found in the Dentate Gyrus and Dorsolateral Frontal Cortex 
Only in Later Stages of AD: 
According to the TDP staging scheme for AD developed by Josephs et al., TDP-
43 is not found in the dentate gyrus until AD TDP Stage III/V and is not found in the 
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dorsolateral frontal cortex until AD TDP Stage V/V (Josephs et al., 2014).  An additional 
study by this group also reported that TDP-43 was found in the substantia nigra in almost 
half (24/51) of an AD TDP Stage IV and Stage V cohort (Jung et al., 2014).  
Unfortunately TDP-43 presence in the substantia nigra for Stage I-III cases was not 
reported, and so no conclusion can be made on which AD TDP stages inclusions may be 
found in the substantia nigra.  However, assuming that inclusions are found in the 
substantia nigra only in AD TDP Stage III and beyond, the CTE TDP staging scheme 
developed in this study would accurately represent TDP-43 pathology even in the context 
of AD. 
 
Why No Stereotypical Spreading Pattern of TDP-43 Pathology in CTE? 
This study demonstrates that TDP-43 inclusions are clearly a feature of CTE, but 
fails to identify a stereotypical spreading pattern of TDP-43 pathology.  In order to 
understand why this would be the case, one must consider the general conditions in 
which TDP-43 inclusions form and also how TDP-43 inclusions are likely developing 
specifically in CTE.   
 
1. Acute Stress Causes a Shift in Localization and Cleavage of TDP-43 
 As stated previously, the significance of the ubiquitination, phosphorylation, 
cleavage, and nuclear clearance of TDP-43, the so-called “pathological changes” of TDP-
43, is unclear.  Many of these changes are seen during the cell’s normal response to 
stress, however, and it is very possible that these changes by themselves are innocuous 
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and not indicative of a pathological process.  TDP-43’s response to oxidative, heat shock, 
and osmotic stress is as follows: 
 
Figure 7: The normal response of TDP-43 to acute stress 
  
 
A.  A Portion of Nuclear TDP-43 Moves to the Cytoplasm 
It is well-established that a portion of nuclear TDP-43 moves to the cytoplasm 
during the cell’s physiological response to stress (Colombrita et al., 2009)(Liu-
Yesucevitz et al., 2010)(V. Ayala et al., 2011)(Dewey et al., 2011)(Iguchi et al., 
2012)(McDonald et al., 2011)(Meyerowitz et al., 2011)(Bentmann et al., 2012)(Higashi 
et al., 2013)(Zhang et al., 2014)(Kabuta et al., 2015)(Kanazawa et al., 2015).  Cell culture 
studies have shown that this nucleus-to-cytoplasm redistribution occurs in as little as 15 
to 30 minutes upon application of stress (Dewey et al., 2011)(Zhang et al., 2014) and is 
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reversible upon removal of stress (McDonald et al., 2011)(Higashi et al., 2013)(Zhang et 
al., 2014).  This shift is not unique to TDP-43, as many other RNA-binding proteins, such 
as hnRNP A1 (van der Houven van Oordt et al., 2000)(Allemand et al., 2005)(Lewis et 
al., 2007), hnRNP A2 (McDonald et al., 2011), hnRNP K (Habelhah et al., 2001), hnRNP 
Q (Quaresma et al., 2009), and RBM45 (Li et al., 2015) have also been shown to 
translocate to the cytoplasm in response to cellular stress. 
Current evidence implicates the c-Jun N-terminal kinase (JNK), extracellular 
signal-regulated kinases (ERK), and p38 signaling cascades in the recruitment of TDP-43 
to cytoplasmic stress granules upon application of stress (V. Ayala et al., 
2011)(Meyerowitz et al., 2011)(Parker et al., 2012)(Higashi et al., 2013)(Moujalled 
2013)(Suzuki et al., 2013).  However, TDP-43 does not appear to be a substrate for any 
of the kinases involved in these pathways, so it is likely that cytosolic TDP-43 is bound 
either directly or to the same transcripts as other RNA-binding proteins that are modified 
in response to stress.   
One very recent study has shown that hnRNP K always colocalizes with TDP-43 
in stress granules and that recruitment of TDP-43 to stress granules is dependent upon 
phosphorylation of hnRNP K by cyclin-dependent kinase 2 (CDK2) (Moujalled et al., 
2015).  This would strongly suggest that TDP-43, which is rapidly shuttling in and out of 
the nucleus bound to mRNAs with other RNA-binding proteins such as hnRNP K 
attached, is recruited to SGs when other proteins bound to it or to the same mRNA 
transcripts are modified in response to stress. 
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B.  Cytoplasmic TDP-43 May be Cleaved by Caspase-3 and/or Calpain 
 Cellular stressors that modify TDP-43 localization may lead to higher levels of 
CTFs in the cytoplasm (Iguchi et al., 2012)(Meyerowitz et al., 2011)(Higashi et al., 
2013).  This increase in CTFs is very likely due to caspase-3 activation caused by stress 
(Liu-Yesucevitz et al., 2010)(Dewey et al., 2011)(Higashi et al., 2013), although it has 
also been reported that low levels of stress which do not lead to caspase-3 activation may 
still lead to significant cleavage of TDP-43 (V. Ayala et al., 2011).  Studies on the 
toxicity of CTFs have led to conflicting results and it is unclear whether CTFs are more 
(Zhang et al., 2009) or less (Voigt et al., 2010)(Suzuki et al., 2011) toxic than FL-TDP-
43. 
 The CTFs created by TDP-43 cleavage are non-functional (Nonaka et al., 
2009)(Zhang et al., 2009)(Nishimoto et al., 2010) for several reasons.  First, both CTF-25 
and CTF-35 lack a nuclear localization sequence and thus always remain in the 
cytoplasm.  Second, CTF-25 lacks RRM1 and cannot bind RNA with the same efficiency 
as FL-TDP-43.  Lastly, it is possible that TDP-43 normally functions as a homodimer and 
that the N-terminal is required for dimerization (Y.-T. Wang et al., 2013)(Budini et al., 
2015), therefore both fragments lack the ability to dimerize. 
It is unknown whether the cleavage of TDP-43 is unique among hnRNPs, as the 
cleavage of other RNA-binding proteins that shift to the cytoplasm due to stress does not 
appear to be an active area of investigation.  Interestingly, other hnRNPs that interact 
with TDP-43 and shift localization in response to stress have been shown to be involved 
in the synthesis of X-linked inhibitor of apoptosis (XIAP) and B-cell lymphoma-extra 
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large (Bcl-xl), two major anti-apoptotic proteins that sequester active caspase-3 (XIAP) 
or prevent caspase activation (Bcl-xl).  Upon phosphorylation, hnRNP A1 binds XIAP 
and Bcl-xl mRNA in the nucleus and shuttles both to the cytoplasm (Roy et al., 2014), 
however once in the cytosol bound hnRNP A1 also inhibits XIAP translation (Lewis et 
al., 2007)(Roy et al., 2014).  HnRNP C1/C2 is a member of the internal ribosome entry 
site (IRES) complex for XIAP (Holcik et al., 2003), and thus is required for the 
translation of XIAP during stress.  Finally, hnRNP K is either a transcription factor for 
XIAP or is involved in post-transcriptional modifications of XIAP mRNA (Xiao et al., 
2013), and also promotes the splicing of Bcl-xl mRNA (Revil 2009).  This involvement 
of TDP-43 binding partners with the production of the anti-apoptotic proteins XIAP and 
Bcl-xl raises the possibility that the cleavage of TDP-43 may be involved in negative 
regulation of activated caspase levels.   
 
C.  FL-TDP-43 and CTFs Are Cleared From the Cytoplasm 
  Upon removal of stress, it is unknown what fraction of cytoplasmic TDP-43 
returns to the nucleus and what fraction is degraded.  Studies have shown that the 
ubiquitin proteasome system (UPS), chaperone-mediated autophagy (CMA), and 
autophagy are all involved in the degradation of soluble FL-TDP-43 and CTFs (Caccamo 
et al., 2009)(Wang et al., 2010)(Huang et al., 2014)(Scotter et al., 2014).  Experimental 
evidence indicates that CTFs are easier for the cell to degrade than FL-TDP-43, as it has 
been shown that CTF levels are more sensitive to inhibition or enhancement of either the 
ubiquitin proteasome system or autophagy (Wang et al., 2010)(Hans et al., 2014)(Huang 
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et al., 2014) and that CTFs have a significantly shorter half-life than FL-TDP-43 
(Pesiridis et al., 2011)(Hans et al., 2014)(Huang et al., 2014).  This has led to the 
hypothesis that cleavage of the protein is a favorable event which enhances TDP-43 
degradation (Huang et al., 2014).   
Inhibition of the ubiquitin proteasome system, but not autophagy, has been shown 
to lead to the formation of TDP-43 aggregates, and so the ubiquitin proteasome system 
enhancement has been proposed as a therapeutic target for TDP-43 proteinopathies.  
Finally, the cell under normal conditions has the ability to clear aggregates that form by 
utilizing a combination of the two systems, with the ubiquitin proteasome system 
degrading soluble TDP species and autophagy clearing oligomers, microaggregates, and 
macroaggregates (Scotter et al., 2014). 
 
2. TDP-43 Inclusions Are a Consequence of Chronic Stress 
Figure 8: Chronic stress results in TDP-43 inclusions 
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It is notable that models of acute stress result in a transient increase in 
cytoplasmic TDP-43 and CTFs, but not in the formation of permanent TDP-43 inclusions 
(Colombrita et al., 2009)(Sato et al., 2009)(Dewey et al., 2011)(Iguchi et al., 
2012)(McDonald et al., 2011)(Meyerowitz et al., 2011)(Higashi et al., 2013)(Zhang et al., 
2014).  If the partial redistribution of TDP-43 from nucleus to cytoplasm is part of an 
intrinsic response meant to help the cell cope with acute stress, it would follow that this 
response shouldn’t result in the formation of pathological inclusions.   
Inclusions are formed, however, in models overexpressing cytoplasmic CTFs 
(Caccamo et al., 2009)(Nonaka et al., 2009)(Ash et al., 2010)(Che et al., 
2011)(Yamashita et al., 2014)(X. Wang et al., 2015), in models with ubiquitin 
proteasome system inhibition (Wang et al., 2010)(Tashiro et al., 2012)(Scotter et al., 
2014), and in models with inhibition of nuclear import (Winton et al., 2008)(Nishimura et 
al., 2010).  Experimental evidence indicates that application of sub-lethal cellular stress 
over a period of weeks or months would lead to not just one of these conditions but all 
three, and it is very likely that TDP-43 inclusions are formed over time through their 
combined efforts.      
Two recent mouse models have provided evidence that chronic, sub-lethal stress 
results in chronically elevated levels of FL-TDP-43 and/or CTFs in the cytoplasm, and 
thus favor inclusion formation.  The first study demonstrated that lipopolysaccharide 
(LPS) treatment, which is known to activate astrocytes and microglia, for a period of two 
months resulted in a sustained increase in both the cytoplasmic-to-nucleus TDP-43 ratio 
and in levels of insoluble TDP-43 species (Correia et al., 2015).  The second study 
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showed that rTBI, which causes long-lasting neuroinflammation (Shitaka et al., 
2011)(Aungst et al., 2014), resulted in increased levels of FL-TDP-43 thirty days after the 
initial injury (Zhang et al., 2015). 
Other studies have also provided evidence that chronic sub-lethal stress conditions 
that cause a shift in TDP-43 localization would result in the inhibition of autophagy and 
UPS by several different mechanisms.  Elevated levels of cytoplasmic CTFs have been 
shown to decrease autophagy and UPS function in a toxic gain-of-function manner 
(Caccamo et al., 2015).  TDP-43 knockdown models have been shown to exhibit 
decreased mRNA and protein levels of autophagy-related 7 (ATG7), a protein necessary 
for autophagy, as well as autophagy inhibition (Bose et al., 2011).  Also, loss of nuclear 
TDP-43 results in the expression of cryptic exons in the ATG4B mRNA transcript, 
another protein necessary for autophagy, which disrupt its translation and promotes 
nonsense-mediated decay of the transcript (Ling et al., 2015).  
Lastly, chronic sub-lethal stress conditions that result in a shift in TDP-43 
localization would very likely result in general impairment of nuclear import.  TDP 
knockdown leads to decreased Ran levels (Sephton et al., 2011)(Ling et al., 2015), which 
is necessary for the nuclear import of many proteins, including TDP-43 itself (Ward et 
al., 2014). 
 
3. Persistent Stress Granules vs. Separate Inclusions Seeded by CTFs  
 Researchers are currently debating whether TDP-43 inclusions are a result of 
stress granules that fail to disassemble or are separate inclusions, possibly seeded by 
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CTFs.  Post-mortem studies on TDP-43 inclusions in ALS and FTLD-TDP tissue have 
yielded conflicting results.  Some groups have reported co-localization of TDP-43 
inclusions with SG markers (Volkening et al., 2009)(Liu-Yesucevitz 2010), while others 
have reported no SG markers within TDP-43 inclusions (Colombrita et al., 2009).  It is 
also very possible that SG markers are not part of the original inclusions but are later 
recruited as the inclusion mature (McGurk et al., 2014), as SG proteins are inherently 
prone to aggregation (Aulas et al., 2015).     
Further muddying the waters is the fact that a distinction may need to be drawn 
between TDP-43 inclusions found within the brain and inclusions found in the spinal 
cord.  Just as ALS and FTLD-TDP inclusions within the brain consistent of mostly CTFs 
and spinal cord inclusions consist of mostly FL-TDP-43 (Igaz et al., 2008), the presence 
of SG markers may depend on whether one is examining the brain or the spinal cord.  
Along these lines, one study has reported finding SG markers in spinal cord TDP-43 
inclusions but not within brain inclusions (Bentmann et al., 2012).         
 Cell culture studies have provided little evidence to settle the debate, largely due 
to the heterogeneity of cell types and stressors used.  Different cell types respond to the 
same stressors in different ways, and different stressors applied to the same cell types 
result in different stress granule dynamics (Aulas et al., 2015).  Notable, however, is the 
fact that studies have reported TDP-43 to be found in small cytoplasmic granules, and not 
SGs, upon exposure to an endogenous oxidative stressor (as opposed to the artificial 
stressors used in most studies) (Kabuta et al., 2015), and also stress at higher levels 
(Zhang et al., 2014) or of longer periods (Higashi et al., 2013).   
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4. Pro-inflammatory Cytokines Likely Drive the Shift in Localization and Then Cleavage 
of TDP-43 Seen During the Acute Response to Injury in Animal Models 
Recent mouse and rat models have shown that a single TBI induces a delayed 
stress-response shift from the nucleus to the cytoplasm and then cleavage of TDP-43 
(Yang et al., 2014)(H. Wang et al., 2015), and notably didn’t result in the formation of 
TDP-43 cytoplasmic inclusions.  However, both models demonstrated a response very 
similar to that seen in mouse models of other injuries, such as axotomy (Moisse, 
Mepham, et al., 2009)(Moisse, Volkening, et al., 2009) and axonal ligation (Sato et al., 
2009).  First, cytoplasmic TDP-43 levels are largely unchanged at 24 hours post-injury, 
then increases begin to reach significance on Day 3 post-injury, followed by cytoplasmic 
TDP-43 levels peaking at Day 7 post-injury, and then finally normalizing by Day 14 
(Moisse, Volkening, et al., 2009)(H.-K. Wang et al., 2015) or Day 28 (Sato et al., 2009) 
post-injury.  This pattern strongly suggests that TDP-43 inclusion formation does not 
occur acutely following injury.  More importantly, it also suggests that the shift to the 
cytoplasm and then cleavage of TDP-43 is not an immediate event that occurs within 
minutes of the primary injury, but is instead due to a common secondary response to 
injury. 
That shared secondary response is very likely the neuroinflammatory response to 
injury.  Models of TBI (d’Avila et al., 2012)(G. Wang et al., 2013)(Y. Wang et al., 2014) 
and axotomy (Moisse, Volkening, et al 2009)(Villacampa et al., 2015) have shown that 
markers of activated microglia, such as Iba-1 and TSPO, exhibit a rise and fall in 
response to injury which mimics that of cytoplasmic TDP-43 and CTFs: activated 
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microglia levels in the injured area are largely unchanged at 24 hours post-injury, then 
increases begin to reach significance on Day 3 post-injury, followed by levels peaking 
around Day 7 post-injury, and then steadily decreasing until near-normal levels are 
reached by Day 28 post-injury.   
Additionally, the polarization of microglia has also been shown to follow this 
pattern in mouse models of spinal cord injury (Kigerl et al., 2009) and TBI (G. Wang et 
al., 2013).  Anti-inflammatory M2 macrophages are initially increased and may 
predominate early, but they return to baseline levels by Day 7 post-injury.  Pro-
inflammatory M1 macrophages, however, are increased starting on Day 3, levels peak 
around Day 7 post-injury, and remain elevated at least 14 days after injury.     
 The question then becomes which particular aspect of neuroinflammation is 
responsible for the shift in localization and then cleavage of TDP-43?  Although activated 
microglia are known to release reactive oxygen species (ROS) that cause oxidative stress 
(Hu et al., 2015) and may stress neurons via other mechanisms, it is likely that the pro-
inflammatory cytokine milieu which leads to M1 microglial activation is also driving 
the initial changes observed in TDP-43.   
One very recent study has demonstrated that TNF-α has the ability to induce the 
shift of TDP-43 from the nucleus to the cytoplasm (Correia et al., 2015).  This is not 
surprising as TNF-α is known to activate the JNK and p38 signaling pathways (Wajant et 
al., 2003), which as previously mentioned are thought to be responsible for the 
cytoplasmic accumulation of TDP-43.  The interleukin-1 family (IL-1) activates the JNK 
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and p38 signaling pathways as well (Weber et al., 2010), and so IL-1α and/or IL-β may 
also be involved in the cytoplasmic accumulation of TDP-43.  
 
From Repetitive mTBI to Chronic Neuroinflammation and then TDP-43 Cellular 
Inclusions 
 The following is a proposed scheme of how rmTBI may be leading to the TDP-43 
inclusions found in cases of CTE: 
 
1. RmTBI causes chronic neuroinflammation 
2. Chronic neuroinflammation causes chronically elevated levels of cytoplasmic 
TDP-43 and CTFs  
3. CTFs aggregate with each other and then FL-TDP-43 to create inclusions and 
cause TDP-43 nuclear clearance 
 
1. rmTBI Causes Chronic Neuroinflammation   
Studies of mice (Loane et al. 2014) and humans (Ramlackhansingh et al., 
2011)(Smith et al., 2013) have reported that a single TBI causes neuroinflammation that 
may persist for months or even years.  Additionally, rTBI induces long-lasting 
neuroinflammation in mouse models (Shitaka et al., 2011)(Aungst et al., 2014)(Petraglia 
et al., 2014) and there is widespread agreement among researchers that rTBI may cause 
chronic neuroinflammation in humans (Coughlin et al., 2015), as well.   
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2. Chronic Neuroinflammation Causes Chronically Elevated Levels of Cytoplasmic TDP-
43 and CTFs 
Chronically activated microglia secrete pro-inflammatory cytokines such as TNF-
α and IL-1β, and studies have shown that pro-inflammatory cytokine levels may remain 
elevated for up to a year after even a single TBI (Kumar et al., 2014).  As mentioned 
previously, chronic stress results in a sustained increase in cytoplasmic TDP-43 CTFs.  
Activation of astrocytes and microglia with LPS treatment for two months has been 
shown to result in a sustained increase in cytoplasmic TDP-43 (Correia et al., 2015) and 
rTBI has also directly been shown to lead to increased levels of cytoplasmic TDP-43 
thirty days after the initial injury (Zhang et al., 2015). 
 
3. CTFs Aggregate with Each Other and then FL-TDP-43 to Create Inclusions 
CTFs are very aggregate-prone, even more so than FL-TDP-43 (Igaz et al., 
2009)(Zhang et al., 2009)(Nonaka et al., 2009), and numerous studies have demonstrated 
that when cytoplasmic CTF levels are increased they form aggregates (Caccamo et al., 
2009)(Nonaka et al., 2009)(Ash et al., 2010)(Che et al., 2011)(Yamashita et al., 2014)(X. 
Wang et al., 2015).  Early aggregates are likely cleared by the combined work of UPS 
and autophagy, but a sustained reduction of nuclear TDP-43 would lead to the 
impairment of these systems and also impaired nuclear import (Bose et al., 
2011)(Sephton et al., 2011)(Ling et al., 2015).  Over time these inefficiencies would 
likely result in CTF aggregates which are not degraded, and these aggregates would have 
the ability to recruit FL-TDP-43 and cause nuclear clearance (Winton et al., 2008)(Yang 
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et al., 2010)(Che et al., 2011)(Budini et al., 2012)(Zhang et al., 2013)(Budini et al., 
2015).  
 
The Need for Further Study of the Relationship Between rmTBI, Inflammation, and 
TDP-43 Inclusions 
The theory that chronic neuroinflammation drives TDP-43 inclusion formation is 
bolstered by the finding of this study that levels of activated microglia correlate with the 
presence of TDP-43 inclusions in the dorsolateral frontal cortex.  However, as TDP-43 
has previously been shown to induce inflammation (Herman et al., 2012) and other 
pathologies are likely present, further research on the relationship between 
neuroinflammation and TDP-43 inclusions in CTE is sorely needed.  
Although inflammation in CTE has not yet been systematically studied, it is likely 
that some regions of the brain are more prone to inflammation upon rmTBI than others 
and also that inflammation hotspots may vary between subjects.  It could be that some 
subjects exhibit more inflammation in the substantia nigra, while others exhibit more 
inflammation in the neocortex or the medial temporal lobe.  If pro-inflammatory 
cytokines do indeed drive the formation of TDP-43 inclusions, this variation in 
inflammation would explain the pattern of TDP-43 pathology found in CTE. 
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APPENDIX 1 
All Cases Sorted According to Present CTE Staging Scheme Based on Tau 
1=TDP-43 present, 0=TDP-43 not present, UN = unexamined or unknown 
Cases in red were not included in this study because they contained more than two 
unexamined regions or were not given a CTE Stage 
 
Case 
Sub. 
Nigra 
Rolandic 
Cortex 
DLF 
Cortex 
Temporal 
Cortex Amygdala 
Entorhinal 
Cortex 
Dentate 
Gyrus 
CTE 
Stage 
1 0 0 0 0 0 0 0 1 
2 0 0 0 0 0 0 0 1 
3 0 0 0 0 0 0 0 1 
4 0 0 0 0 1 1 0 1 
5 1 1 0 0 0 0 0 1 
6 0 UN UN UN 0 0 0 1 
                  
7 0 0 0 0 0 0 0 2 
8 0 0 0 0 0 0 0 2 
9 0 0 0 0 0 0 0 2 
10 0 0 0 0 0 0 0 2 
11 0 0 0 0 0 0 0 2 
12 0 0 0 0 0 0 0 2 
13 0 0 0 0 0 0 0 2 
14 0 0 0 0 0 0 0 2 
15 0 0 0 0 0 0 0 2 
16 0 0 0 0 0 0 0 2 
17 0 0 0 0 0 0 0 2 
18 0 0 0 0 0 0 0 2 
19 0 0 0 0 0 0 0 2 
20 0 0 0 0 0 UN 0 2 
21 0 0 0 0 UN UN 0 2 
22 0 UN 0 UN 0 0 0 2 
23 1 0 0 0 0 0 0 2 
24 0 1 1 1 0 0 0 2 
25 1 1 1 0 0 0 0 2 
26 1 1 1 0 0 1 0 2 
27 UN 0 0 0 UN UN UN 2 
28 1 UN UN 1 0 UN 0 2 
29 1 UN UN 1 1 UN 1 2 
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30 UN 1 UN UN UN UN UN 2 
                  
31 0 0 0 0 0 0 0 3 
32 0 0 0 0 0 0 0 3 
33 0 0 0 0 0 0 0 3 
34 0 0 0 0 0 0 0 3 
35 0 0 0 0 0 0 0 3 
36 0 0 0 0 0 0 0 3 
37 0 0 0 0 0 0 0 3 
38 1 0 0 0 0 0 0 3 
39 1 0 0 0 0 0 0 3 
40 0 0 1 0 1 0 0 3 
41 1 0 0 0 1 1 UN 3 
42 0 0 0 0 1 1 1 3 
43 1 0 0 0 1 1 1 3 
44 1 0 0 1 1 1 1 3 
45 0 1 1 0 1 1 1 3 
46 0 1 1 0 1 UN 1 3 
47 1 1 1 1 1 1 1 3 
48 1 UN UN 1 1 UN 1 3 
49 0 UN 0 UN 0 UN UN 3 
50 0 UN 0 UN 0 UN UN 3 
51 0 UN UN UN 0 UN 0 3 
52 UN UN UN UN UN UN 0 3 
53 UN UN UN UN UN UN UN 3 
                  
54 0 0 0 0 0 UN 0 4 
55 1 0 1 0 0 0 0 4 
56 0 UN 1 0 0 UN 1 4 
57 1 0 0 1 1 0 1 4 
58 1 1 1 1 1 1 1 4 
59 1 UN UN UN 1 UN 1 4 
60 1 UN UN UN 1 UN 0 4 
                  
61 1 1 1 1 0 0 0 UN 
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APPENDIX 2 
All Studied Cases Sorted According to Proposed TDP Staging Scheme for CTE  
 
0=No TDP-43, 1=1-4 TDP-43 inclusions, 2=5-10 TDP-43 inclusions, 3=Greater than 10 
TDP-43 inclusions, UN = unexamined or unknown 
 
Case 41 not given a TDP Stage because dentate gyrus not examined 
 
Case 
TDP 
Stage 
Sub. 
Nigra 
Roland. 
Ctx 
DLF 
Ctx 
Temp. 
Ctx Amyg. 
Entorh. 
Ctx DG 
CTE 
Stage 
1 0 0 0 0 0 0 0 0 1 
2 0 0 0 0 0 0 0 0 1 
3 0 0 0 0 0 0 0 0 1 
7 0 0 0 0 0 0 0 0 2 
8 0 0 0 0 0 0 0 0 2 
9 0 0 0 0 0 0 0 0 2 
10 0 0 0 0 0 0 0 0 2 
11 0 0 0 0 0 0 0 0 2 
12 0 0 0 0 0 0 0 0 2 
13 0 0 0 0 0 0 0 0 2 
14 0 0 0 0 0 0 0 0 2 
15 0 0 0 0 0 0 0 0 2 
16 0 0 0 0 0 0 0 0 2 
17 0 0 0 0 0 0 0 0 2 
18 0 0 0 0 0 0 0 0 2 
19 0 0 0 0 0 0 0 0 2 
20 0 0 0 0 0 0 UN 0 2 
21 0 0 0 0 0 UN UN 0 2 
22 0 0 UN 0 UN 0 0 0 2 
31 0 0 0 0 0 0 0 0 3 
32 0 0 0 0 0 0 0 0 3 
33 0 0 0 0 0 0 0 0 3 
34 0 0 0 0 0 0 0 0 3 
35 0 0 0 0 0 0 0 0 3 
36 0 0 0 0 0 0 0 0 3 
37 0 0 0 0 0 0 0 0 3 
54 0 0 0 0 0 0 UN 0 4 
4 0 0 0 0 0 1 1 0 1 
Case 
TDP 
Stage 
Sub. 
Nigra 
Roland. 
Ctx 
DLF 
Ctx 
Temp. 
Ctx Amyg. 
Entorh. 
Ctx DG 
CTE 
Stage 
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23 1 1 0 0 0 0 0 0 2 
38 1 2 0 0 0 0 0 0 3 
39 1 1 0 0 0 0 0 0 3 
56 1 0 UN 1 0 0 UN 0 4 
5 1 1 1 0 0 0 0 0 1 
40 1 0 0 1 0 1 0 0 3 
24 1 0 1 1 1 0 0 0 2 
55 2 2 0 1 0 0 0 0 4 
25 2 1 1 1 0 0 0 0 2 
42 2 0 0 0 0 1 2 1 3 
26 2 3 3 3 0 0 1 0 2 
46 2 0 1 1 0 3 UN 3 3 
43 2 1 0 0 0 2 2 2 3 
57 2 2 0 0 1 2 0 2 4 
45 2 0 1 1 0 1 1 1 3 
44 2 2 0 0 2 2 2 2 3 
58 3 2 1 1 3 3 3 3 4 
47 3 1 1 1 1 3 2 1 3 
          
41 UN 1 0 0 0 2 2 UN 3 
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APPENDIX 3 
 
Studies of TDP-43 Pathology in Cognitively Normal Subjects 
 
Study TDP+ TDP+ 
Mean 
Age 
at 
Death 
TDP- 
Mean 
Age 
at 
Death 
Description 
Nakashima-
Yasuda et 
al., 2007 
1/33 98 75 
±12 
Only medial temporal lobe examined.  1 case with 
TDP found in CA1.   
Wilson et 
al., 2011 
2/63 82 71 Examined amygdala initially in all cases, both TDP+ 
cases then examined in frontal cortex, superior 
temporal cortex, cingulate cortex, anterior and 
posterior hippocampus, striatum, midbrain, pons, 
medulla, and spinal cord.  Concluded TDP in 
amygdala only.  
Arnold et 
al., 2013 
40/110 88 
±6 
86 
±6 
Only medial temporal lobe examined in all cases.  All 
40 cases with TDP in either amygdala, 
parahippocampal gyrus, and/or subiculum.   
Kovacs et 
al., 2013 
4/51 UN UN Specific TDP+ regions not reported 
Nascimento 
et al., 2015 
34/323 74 
±13 
69 
±11 
Initially examined amygdala, hippocampal formation, 
and inferior/middle temporal gyrus only.  If TDP+, 
then also examined anterior cingulate gyrus, superior 
frontal gyrus, and superior colliculus.   
- Of 12 cases TDP+ in dentate gyrus: 1 case 
with no other regions TDP+, 4 cases with 1 
other TDP+ region.  
- 2 of 6 cases with >3 TDP+ regions are TDP- 
in dentate gyrus.  
TDP Staging Scheme mischaracterizes extent and 
severity of TDP-43 pathology in 7/323 cases 
(2.2%).  
Uchino et 
al., 2015 
55/136 81 
±9 
77 
±10 
Examined anterior hippocampus, amygdala, medulla, 
and lumbar spinal cord.  TDP found most often in 
uncus, also found in inferior olivary complex and 
spinal cord. 
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